Allegheny Financial Group’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-2,875
Closed -$10.7K 171
2022
Q4
$10.7K Buy
2,875
+1,200
+72% +$5.3K ﹤0.01% 168
2022
Q3
$8K Buy
+1,675
New +$9.32K ﹤0.01% 160

Other funds holding ORTX

Allegheny Financial Group's ORTX Position: Q1 2023 in Review

Allegheny Financial Group sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 2,875 shares — an estimated $10.7K sold.

Allegheny Financial Group first reported a position in ORTX in Q3 2022 and held it in 2 quarters. The position peaked at $10.7K in Q4 2022. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

  • Allegheny Financial Group reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Allegheny Financial Group sold 2,875 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $10.7K.
  • Allegheny Financial Group first reported a position in Orchard Therapeutics plc American Depositary Shares in Q3 2022 and held it in 2 quarters.
  • Allegheny Financial Group's Orchard Therapeutics plc American Depositary Shares position peaked at $10.7K in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Allegheny Financial Group's 13F filing for Q1 2023, filed 5 May 2023.